Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats

Hypertension

Volumn 48, Issue 4, 2006, Pages 677-684

  Oelze, Matthias ^a   Daiber, Andreas ^a   Brandes, Ralf P ^b   Hortmann, Marcus ^c   Wenzel, Philip ^a   Hink, Ulrich ^a   Schulz, Eberhard ^a   Mollnau, Hanke ^a   Von Sandersleben, Alexandra ^d   Kleschyov, Andrei L ^a   Mülsch, Alexander ^a   Li, Huige ^c   Förstermann, Ulrich ^c   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiotensin II; Endothelium; Nitric oxide synthase; Oxidative stress; Vasodilation

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ANTIOXIDANT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEMOGLOBIN; HYDROETHIDINE; LUCIGENIN; MESSENGER RNA; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; PHORBOL ESTER; PROTEIN; PROTEIN NOX1; PROTEIN P67PHOX; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; VASODILATOR AGENT; 1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; 10,10' DIMETHYL 9,9' BIACRIDINIUM; 10,10'-DIMETHYL-9,9'-BIACRIDINIUM; ACRIDINE DERIVATIVE; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROETHIDINE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; L 012; LUMINESCENT AGENT; LUMINOL; NEUTROPHIL CYTOSOL FACTOR 67K; NOS3 PROTEIN, RAT; PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CELL STRAIN HEK293; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; BLOOD VESSEL; CELL LINE; DRUG ANTAGONISM; FLUORESCENCE; HEART MUSCLE; LUMINESCENCE; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ACRIDINES; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANIMALS; BENZOPYRANS; BLOOD VESSELS; CELL LINE; CYCLIC GMP; DICARBETHOXYDIHYDROCOLLIDINE; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FLUORESCENCE; HEMOGLOBINS; HUMANS; LUMINESCENCE; LUMINESCENT AGENTS; LUMINOL; MALE; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PHOSPHOPROTEINS; RAC1 GTP-BINDING PROTEIN; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SUPEROXIDES;

EID: 33750600184     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000239207.82326.29     Document Type: Article

References (28)

1. Hamilton C. Nitric oxide, oxidative stress and hypertension: A complex equation. J Hypertens. 2002;20:1055-1056.
2. Touyz RM. Reactive oxygen species in vascular biology: Role in arterial hypertension. Expert Rev Cardiovasc Ther. 2003;1:91-106.
3. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
4. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.
5. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888-894.
6. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
7. Katusic ZS. Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol. 2001;281:H981-H986.
8. Taylor TA, Pollock JS, Pollock DM. Down-regulation of soluble guanylyl cyclase in the inner medulla of DOCA-salt hypertensive rats. Vascul Pharmacol. 2003;40:155-160.
9. Ungvari Z, Csiszar A, Kaminski PM, Wolin MS, Koller A. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol. 2004;165:219-226.
10. Asbrink S, Zickert A, Bratt J, Gyllenhammar H, Palmblad J. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol. 2000;59:1007-1013.
11. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, Wendt M, Walter U, Geiger C, Agrawal R, Kleschyov AL, Meinertz T, Munzel T. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23:615-621.
12. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van Gorsel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS, van Der Zee R. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
13. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153.
14. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
15. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379.
16. Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schuler S, Schulze-Osthoff K. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001;49:430-439.
17. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 2005;112:2677-2685.
18. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation. 2005;112:2668-2676.
19. Sun YP, Zhu BQ, Sievers RE, Glantz SA, Parmley WW. Metoprolol does not attenuate atherosclerosis in lipid-fed rabbits exposed to environmental tobacco smoke. Circulation. 1994;89:2260-2265.
20. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
21. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22.
22. Mollnau H, Oelze M, August M, Wendt M, Daiber A, Schulz E, Baldus S, Kleschyov AL, Materne A, Wenzel P, Hink U, Nickenig G, Fleming I, Munzel T. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol. 2005;25:2554-2559.
23. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, MacHarzina R, Brasen JH, Meinertz T, Munzel T. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999;55:252-260.
24. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, Walter U, Skatchkov M, Meinertz T, Munzel T. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric Oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000;87:999-1005.
25. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
26. Brandes RP, Kreuzer J. Vascular NADPH oxidases: Molecular mechanisms of activation. Cardiovasc Res. 2005;65:16-27.
27. Shibata MC, Flather MD, Bohm M, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Parkhomenko A, Soler-Soler J, Tavazzi L, Toman J, Van Veldhuisen DJ, Coats AJ, Poole-Wilson P. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol. 2002;86:77-85.
28. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589-596.